

ARTICLE

Received 17 Mar 2014 | Accepted 17 Jul 2015 | Published 14 Sep 2015

DOI: 10.1038/ncomms9111

OPEN

Improved imputation of low-frequency and rare variants using the UK10K haplotype reference panel

Jie Huang^{1,*}, Bryan Howie^{2,*}, Shane McCarthy¹, Yasin Memari¹, Klaudia Walter¹, Josine L. Min³, Petr Danecek¹, Giovanni Malerba⁴, Elisabetta Trabetti⁴, Hou-Feng Zheng^{5,6,7}, UK10K Consortium[†], Giovanni Gambaro⁸, J. Brent Richards^{5,6,7,9}, Richard Durbin¹, Nicholas J. Timpson³, Jonathan Marchini^{10,11,#} & Nicole Soranzo^{1,12,#}

Imputing genotypes from reference panels created by whole-genome sequencing (WGS) provides a cost-effective strategy for augmenting the single-nucleotide polymorphism (SNP) content of genome-wide arrays. The UK10K Cohorts project has generated a data set of 3,781 whole genomes sequenced at low depth (average 7x), aiming to exhaustively characterize genetic variation down to 0.1% minor allele frequency in the British population. Here we demonstrate the value of this resource for improving imputation accuracy at rare and low-frequency variants in both a UK and an Italian population. We show that large increases in imputation accuracy can be achieved by re-phasing WGS reference panels after initial genotype calling. We also present a method for combining WGS panels to improve variant coverage and downstream imputation accuracy, which we illustrate by integrating 7,562 WGS haplotypes from the UK10K project with 2,184 haplotypes from the 1000 Genomes Project. Finally, we introduce a novel approximation that maintains speed without sacrificing imputation accuracy for rare variants.

¹The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1HH, UK. ²Adaptive Biotechnologies Corporation, Seattle Washington 98102, USA. ³MRC Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Oakfield House, Oakfield Grove, Clifton, Bristol BS8 2BN, UK. ⁴Biology and Genetics, Department of Life and Reproduction Sciences, University of Verona, 37134, Italy. ⁵Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2. ⁶Department of Medicine, McGill University, Montreal, Quebec, Canada H3A 1B1. ⁷Department of Human Genetics, McGill University, Montreal, Quebec, Canada H3A 1B1. ⁸Division of Nephrology and Dialysis, Institute of Internal Medicine, Renal Program, Columbus-Gemelli University Hospital, Catholic University, Rome, Italy. ⁹The Department of Twin Research & Genetic Epidemiology, King's College London, St Thomas' Campus, Lambeth Palace Road, London SE1 7EH, UK. ¹⁰Department of Statistics, University of Oxford, 1 South Parks Road, Oxford OX1 3TG, UK. ¹¹Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN, UK. ¹²Department of Haematology, University of Cambridge, Long Road, Cambridge CB2 0PT, UK. * These authors contributed equally to this work. # These authors jointly supervised this work. [†] A full list of consortium members appears at the end of the paper. Correspondence and requests for materials should be addressed to J.M. (email: marchini@stats.ox.ac.uk) or to N.S. (email: ns6@sanger.ac.uk).

Statistical inference of missing genotypes (imputation), where genotyped markers from SNP arrays are used to impute unobserved genotypes from haplotype panels such as the HapMap data, has been instrumental to the discovery of thousands of complex trait loci in meta-analyses of genome-wide association studies (GWAS)^{1,2}. Whole-genome sequencing (WGS) provides near-complete characterization of genetic variation, but it is still prohibitive for researchers to conduct WGS on the large number of samples that are needed to study phenotypic associations of low-frequency and rare genetic variants (minor allele frequency (MAF) <1–5% and <1% respectively). Recently, the 1000 Genomes Project (1000GP) has provided phased haplotypes for more than a thousand samples from diverse worldwide populations, thereby boosting variant coverage and imputation quality, particularly for variants with MAFs of 1–5% (ref. 3). Imputation using this large reference panel has been made computationally efficient by pre-phasing of GWAS samples⁴ and approximations that select a subset of reference haplotypes⁵.

Here we describe a novel WGS imputation panel comprising 3,781 samples from the UK10K Cohorts project⁶. We show that this reference panel greatly increases accuracy and coverage of low-frequency variants relative to a panel of 1,092 individuals from the 1000GP. In addition, we show that imputation accuracy can improve substantially when reference haplotypes are re-phased after initial WGS genotype calling. We present a practical solution for combining imputation reference panels to increase variant coverage, and we introduce a new approximation that maintains the speed of existing approximations while achieving higher accuracy.

Results

The UK10K imputation panel. The UK10K Cohorts Project⁶ includes two population samples from the UK (<http://www.uk10k.org/studies/cohorts.html>). The TwinsUK registry comprises unselected, mostly female volunteers ascertained from the general population through national media campaigns in the UK⁷. The Avon Longitudinal Study of Parents and Children (ALSPAC) is a population-based birth cohort study that recruited >13,000 pregnant women resident in Bristol (formerly Avon), UK⁸. A total of 1,990 individuals from TwinsUK and 2,040 individuals from ALSPAC were consented for sequencing. Variant sites and genotype likelihoods were called using SAMtools⁹, and genotypes were refined and phased using Beagle¹⁰, following similar procedures to the 1000GP (Methods)³. After QC, 45,492,035 variant sites (42,001,210 single-nucleotide variants and 3,490,825 insertion/deletions (INDELs)) were retained (Table 1) in 1,854 and 1,927 individuals in the TwinsUK and ALSPAC panels, respectively. We downloaded phased haplotypes from 1000GP (Phase 1 integrated v3), which include a total of 39,527,072 sites. We

developed new software functionality for merging haplotype reference panels (Supplementary Note 1 and Supplementary Fig. 1). For imputation using the merged panel, here we removed multi-allelic sites and further excluded variants seen only in 1000GP or seen only once in the combined 1000GP + UK10K data set (singletons, see footnote of Table 1 for details). The choice of removing 1000GP-only and singleton sites was designed to specifically evaluate the impact of the increased European-ancestry panel in UK10K vis-à-vis the smaller 1000GP EUR panel. A total of 26,032,603 sites were retained for the imputation reference panel of UK10K panel, and 32,449,428 sites for the imputation reference panel of 1000GP. Given that 16,122,337 sites exist in both panels, combining the two reference panels results in a total of 42,359,694 sites. Overall, 5,775,752 (35.8%) of the overlapping sites had frequencies >5% and another 2,451,738 (15.2%) had frequencies between 1 and 5% in the UK10K sample.

Imputation evaluation of UK10K versus 1000GP. As a first assessment of the UK10K reference panel, we performed a leave-one-out cross-validation on a pseudo-GWAS of UK ancestry, corresponding to a sub-sample of 1,000 individuals from the UK10K WGS data set (500 from TwinsUK and 500 from ALSPAC). For this experiment, we removed each sample from the reference panel in turn, selected 13,413 sites on chromosome 20 from the Illumina 610k bead chip (pseudo-GWAS panel), and imputed all other sites on this chromosome from a given reference panel. We conducted the imputation with three haplotype reference panels: the 1000GP Phase 1 panel, the ‘original’ UK10K panel produced by initial genotype refinement and haplotyping with BEAGLE, and a ‘re-phased’ UK10K panel that was generated by using SHAPEIT v2 (ref. 11) to estimate haplotypes from the BEAGLE genotypes (Supplementary Fig. 2). The accuracy of imputed variants was calculated as the squared Pearson correlation coefficient (r^2) between imputed genotype dosages in (0–2) and masked sequence genotypes in (0,1,2). The results were stratified into non-overlapping MAF bins for plotting.

The results of this experiment are shown in Fig. 1a, which focuses on variants with MAF <5%. The corresponding plot for all MAF is shown in Supplementary Fig. 3. Both UK10K reference panels (blue dotted and solid lines) produced higher accuracy than the 1000GP panel (black line), with greater gains at lower frequencies. These trends were expected due to the larger sample size and better ancestry matching of the UK10K reference panel to the pseudo-GWAS data. Notably, the UK10K reference panel yielded much higher imputation accuracy after re-phasing with SHAPEIT v2 (solid versus dotted blue lines): the mean r^2 at low frequencies increased by >0.1 (20%) after re-phasing, which implies a substantial boost in the power to detect associations. A large imputation panel is a resource that can inform a variety of association studies, so these results suggest that taking the time to improve a WGS panel’s haplotype quality could have substantial downstream benefits.

Table 1 | Descriptives for the UK10K and 1000GP reference panels used for imputation.

	UK10K	1000GP(Phase 1 v3)	Combined	Overlap
N samples (% European)	3,781 (100%)	1,092 (34.7%)	4,873	—
N total sites in final release	45,492,035	39,527,072	—	—
N total sites after filtering ^a	26,032,603	32,449,428	42,359,694	16,122,337
Autosome SNPs	23,411,635	29,797,220	38,238,102	14,970,753
Autosome INDELs	1,698,262	1,370,819	2,407,858	661,223
Chr X SNPs	858,380	1,223,328	1,612,230	469,478
Chr X INDELs	64,326	58,061	101,504	20,883

^aFor UK10K, the following sites were excluded: 18,180,633 singletons that do not exist in 1000GP, 1,064,168 multi-allelic sites and 214,631 mis-matched alleles sites. For 1000GP, the following sites were excluded: 7,053,246 singletons that do not exist in UK10K, 23,932 sites with a SNP and an INDEL at the same position and 443 within large structural deletions. The bold indicates that these four categories of variants are subsets of the N total sites after filtering.




Figure 1 | Imputation performance for different imputation strategies and reference panels. (a) Imputation accuracy in the UK10K pseudo-GWAS test panel using reference panels from 1000GP (black) and UK10K (blue). The ‘original’ UK10K reference panel (dotted blue line) was produced by standard genotype refinement of low-coverage sequencing data, whereas the ‘rephased’ reference panel (solid blue line) was produced by running SHAPEIT v2 on the genotypes called by BEAGLE to improve haplotype accuracy. (b) Number of imputed variants in UK10K pseudo-GWAS panel as a function of predicted minor allele frequency in the study cohort (x-axis), expected imputation r^2 (density of shading), and reference panel: 1000GP (black), UK10K (blue), or combined UK10K and 1000GP (red). Confidently imputed variants are shown in the bottom segment of each bar for easy comparison. Note that expected r^2 tends to be larger than true r^2 . (c) As in b, but using the INCIPE cohort (representative of the general Italian population) as a pseudo-GWAS panel. (d) Imputation accuracy in the INCIPE pseudo-GWAS panel using the UK10K reference panel and different imputation approximations. Results are provided for a run that used all reference haplotypes with no approximation (blue solid line), a run that used an established Hamming distance approximation (orange solid line), and a run that used a new tract sharing approximation (orange dashed line).

Evaluation of combining two reference panels. It is becoming increasingly common for investigators to conduct their own WGS of particular study populations, and a natural goal is to combine these data sets with publicly available reference panels (such as 1000GP) to increase sample size and variant coverage for imputation of GWAS cohorts. This is already a ubiquitous problem, and there are multiple ways to integrate WGS data sets that require different levels of data sharing and computing power. In this work, we suggest a simple approach that should be feasible for most groups that have sufficient computational resources for GWAS imputation. Our approach is to take two-phased reference panels and reciprocally impute them up to the union set of variants, then use this combined panel for GWAS imputation; we have implemented this functionality in IMPUTE2 (ref. 1) (details are shown in Supplementary Table 1 and Supplementary Note 1).

To evaluate this new functionality, we used a combined 1000GP + UK10K panel to perform imputation with pseudo-GWAS data sets drawn from the UK and Italy (details below). In each of these comparisons, we imputed all available reference variants and stratified them by expected r^2 , which is a confidence metric produced by IMPUTE2 (also known as ‘info’ in the software output). Unlike the true r^2 metric, which is usually calculated by masking and imputing ‘truth’ genotypes, the expected r^2 metric allows direct comparisons of reference panel performance across study populations that have substantially

different sets of genotyped truth variants. We have found that predicted r^2 values tend to be larger than true r^2 values for low-frequency variants (for example, only $\sim 2/3$ of variants with expected $r^2 \geq 0.4$ and $MAF < 5\%$ have true $r^2 \geq 0.4$), so the absolute numbers of high-confidence imputed variants reported in this section should be treated as upper bounds; the emphasis is on qualitative patterns between reference panels and between study populations.

Figure 1b shows how a combined 1000GP + UK10K panel (red) produced by this method performed against each panel separately (1000GP, black; UK10K, blue) when imputing a pseudo-GWAS of UK ancestry. For these evaluations, we used UK10K and 1000GP haplotype panels rephased using SHAPEIT v2, which were previously shown to yield more accurate imputation compared with the corresponding ‘original’ haplotypes. The combined and UK10K panels produced very similar numbers of high-confidence (expected $r^2 > 0.8$) variants at MAFs of 0.5% and higher, implying that the combined panel is neither helpful nor harmful for imputing common and low-frequency variants when a large, population-specific panel is available. On chromosome 20, the combined panel added 2,356 high-confidence rare variants that were not captured by the UK10K panel ($MAF < 0.5\%$; 4% increase), which could reflect mutations that have drifted to very low frequencies in the UK but persist on the same haplotype background elsewhere in Europe^{5,12}.

Figure 1c provides the results of a similar evaluation carried out in a population in northern Italy (INCIPE cohort), also based on chromosome 20. The INCIPE cohort was newly genotyped in this study, using Illumina HumanCoreExome-12v1-1 arrays. After stringent QC (Online Supplementary Methods), chromosome 20 genotypes from 6,300 SNPs in 2,145 participants were used to drive imputation with each reference panel. In this data set the UK10K reference panel outperformed the 1000GP panel in all frequency bins, despite the fact that the 1000GP includes a panel (TSI, or ‘Toscani in Italia’) that is genetically more similar to the study population. This confirms previous findings¹³ that reference sample size is often more important than population matching. As before, the combined 1000GP + UK10K panel yielded a larger number of high-confidence imputed variants than the UK10K panel alone—here, the combined panel added 7,466 well-imputed variants with $MAF < 0.5\%$, for a 40% increase in rare variants over the UK10K panel (Fig. 1b). These results suggest that it can be especially useful to combine the strengths of multiple panels when a large, population-specific reference set is not available for a particular GWAS population.

Imputation metrics for choosing reference haplotypes. In the course of our analyses, we noticed that some rare variants were imputed well when using the entire UK10K reference panel to drive imputation, yet poorly when using IMPUTE2’s k_{hap} approximation (all of the results described above are based on using the full reference panel). This approximation reduces the computational cost of imputation by using a region-wide (for example, across a 3MB imputation chunk) Hamming distance metric to reduce the number of reference haplotypes used by a given GWAS haplotype (see also Supplementary Fig. 4). Our investigation of these variants led us to develop a new approximation that uses local (rather than region-wide) haplotype sharing to choose a subset of reference haplotypes (see Supplementary Note 2 for details). This approximation delivers a speed boost similar to that of the existing k_{hap} approximation, but it does not sacrifice imputation accuracy at rare and low-frequency variants. For example, Fig. 1d shows the results of imputing the INCIPE pseudo-GWAS data with the UK10K reference panel (see also Supplementary Fig. 5). The full UK10K panel produced the highest accuracy (solid blue line), whereas the k_{hap} approximation based on Hamming distance (solid orange line) was less accurate for SNPs with $MAF < 5\%$. By contrast, our new approximation based on haplotype tract sharing (dashed orange line) was nearly as accurate as the full reference panel, at ~10% of the computing time (see also Supplementary Fig. 6). All of these strategies for choosing reference haplotypes improved slightly (1–5% increase in mean r^2) when the 1000GP haplotypes were added to the UK10K panel, but their relative accuracies remained similar to those shown in Fig. 1d. Further speed improvements are possible for a modest price in accuracy (see Supplementary Note 2).

Discussion

As WGS becomes a standard tool for population and disease genetics, there will be many questions about how to design sequencing studies, how to process the data, how to combine data across studies, and how to limit the computational costs of downstream analysis. With data from one of the most ambitious population sequencing studies to date, we have demonstrated the value of a large, UK-specific reference panel for imputation in British cohorts and in other European populations. Our results show that state-of-the-art phasing methods like SHAPEIT v2 are essential for creating high-quality haplotype panels. Combining WGS data across studies is a desirable goal, and we have implemented an approach in IMPUTE2 that can integrate sets of

phased haplotypes to produce a unified reference panel; other strategies for combining WGS data may improve haplotype quality, but our approach has the advantage of being relatively simple and fast. Finally, we have proposed a new approximation that will help reduce the trade-off between imputation speed and accuracy as reference panels continue to grow. The novel strategies we have presented will inform other investigators who wish to use WGS reference panels for imputation, and they will spur additional methods development as population sequencing resources proliferate.

Future efforts to combine multiple large low-coverage sequencing datasets into a substantially larger haplotype resource will likely increase imputation performance, especially at variants with frequencies below 0.1%. We generated a combined reference panel with 42.4 million imputable sites, which is much larger than the 26.6 million imputable sites in the UK10K panel or 32.5 million imputable sites in the 1000GP panel. The UK10K WGS haplotypes for 3,781 samples are available for download from the European Genome-phenome Archive (<https://www.ebi.ac.uk/ega/>) under managed access conditions (http://www.uk10k.org/data_access). The functionality described in this work is available from the IMPUTE2 website (http://mathgen.stats.ox.ac.uk/impute/impute_v2.html) and the SHAPEIT v2 website (https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html).

Methods

Sample collections. The ALSPAC is a long-term health research project. More than 14,000 mothers enrolled during pregnancy in 1991 and 1992, and the health and development of their children has been followed in great detail ever since⁸. A random sample of 2,040 study participants was selected for WGS. The ALSPAC Genetics Advisory Committee approved the study and all participants gave signed consent to the study.

The Department of Twin Research and Genetic Epidemiology, is the UK’s only twin registry of 11,000 identical and non-identical twins between the ages of 16 and 85 years (ref. 14). The database used to study the genetic and environmental aetiology of age-related complex traits and diseases. The St Thomas’s Hospital Ethics Committee approved the study and all participants gave signed consent to the study.

Sequence data production. Low-read depth WGS was performed in the TwinsUK and ALSPAC as part of the UK10K project. Methods for the generation of these data are described in detail as follows⁶:

Low coverage WGS was performed at both the Wellcome Trust Sanger Institute and the Beijing Genomics Institute (BGI). DNA (1–3 µg) was sheared to 100–1,000 bp using a Covaris E210 or LE220 (Covaris, Woburn, MA, USA). Sheared DNA was size selected to Illumina paired-end DNA library preparation. Following size selection (300–500 bp insert size), DNA libraries were sequenced using the Illumina HiSeq platform as paired-end 100 base reads according to manufacturer’s protocol.

Data generated at the Sanger Institute and BGI were aligned to the human reference separately by the respective centres. The BAM files³ produced from these alignments were submitted to the European Genome-phenome Archive. The Vertebrate Resequencing Group at the Sanger Institute then performed further processing.

Sequencing reads that failed QC were removed using the Illumina GA Pipeline, and the rest were aligned to the GRCh37 human reference, specifically the reference used in Phase 1 of the 1000GP (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/reference/human_g1k_v37.fasta.gz). Reads were aligned using BWA (v0.5.9-r16) (ref. 4). This involved the following steps:

1. Index the reference fasta file:
`bwa index -a bwtsv <reference_fasta>`
2. For each fastq file:
`bwa aln -q 15 -f <sai_file> <reference_fasta> <fastq_file>`
3. Create SAM files [sam] using bwa sampe for paired-end reads:
`bwa sampe -f <sam_file> <reference_fasta> <sai_files> <fastq_files>`
4. Create sorted BAM from SAM. For alignments created at the Sanger this was done using Picard (v1.36; <http://picard.sourceforge.net/>) SamFormatConverter and samtools (v0.1.11) sort. For alignments created at the BGI, this was done using samtools (v0.1.8) view and samtools sort.
5. PCR duplicates reads in the Sanger alignments were marked as duplicate using the Picard MarkDuplicates, whereas in the BGI alignments they were removed using samtools rmdup.

Further processing to improve SNP and INDEL calling, including realignment around known INDELS, base quality score recalibration, addition of BAQ tags,

merging and duplicate marking follows that used for Illumina low coverage data in Phase 1 of the 1000GP⁵. Software versions used for UK10K for the steps described in that section were GATK version 1.1-5-g6f43284, Picard version 1.64 and samtools version 0.1.16.

SNP and INDEL calls were made using samtools/bcftools (version 0.1.18-r579; <https://github.com/samtools/samtools/commit/70c740acc966321754c6bfcc6d61ea056480638>) by pooling the alignments from 3,910 individual low coverage BAM files. All-samples and all-sites genotype likelihood files (bcf) were created with the samtools mpileup command

```
samtools mpileup -EDVSp -C50 -m3 -F0.2 -d 8000 -P ILLUMINA -g
with the flags:
```

C = Coefficient for downgrading mapping quality for reads containing excessive mismatches.

d = At a position, read maximally d reads per input BAM

Variants were then called using the following bcftools command to produce a VCF file⁷

```
bcftools view -m 0.9 -vcgN.
```

For calling on chromosome X and Y, the following settings were applied. The pseudo-autosomal region (PAR) was masked on chromosome Y in the reference fasta file. Male samples were called as diploid in the PAR on chromosome X, and haploid otherwise. No calls were made on chromosome Y for female samples. Diploid/haploid calls were made using the -s option in bcftools view. The PAR regions were: X-PAR1 (60,001-2,699,520); X-PAR2 (154,931,044-155,260,560); Y-PAR1 (10,001-2,649,520); Y-PAR2 (59,034,050-59,363,566). The pipeline (run-mpileup) used to create the calls is available from <https://github.com/VertebrateResequencing/vr-codebase/tree/develop>.

The observation of spikes in the insertion/deletion ratio in sequencing cycles of a subset of the sequencing runs were linked to the appearance of bubbles in the flow cell during sequencing. To counteract this, the following post-calling filtering was applied. The bamcheck utility from the samtools package was used to create a distribution of INDELS per sequencing cycle. Lanes with INDELS predominantly clustered at certain read cycles were marked as problematic, specifically where the highest peak was 5x bigger than the median of the distribution. The list of problematic lanes included 159 samples. In the next step we checked mapped positions of the affected reads to see if they overlapped with called INDELS, which they did for 1,694,630 called sites. The genotypes and genotype likelihoods of affected samples were then set to the reference genotype unless there was a support for the indel also in a different, unaffected lane from the same sample. In total, 140,163 genotypes were set back to reference and 135,647 sites were excluded by this procedure. Note that this step was carried out on raw, unfiltered calls prior to Variant Quality Score Recalibration (VQSR) filtering.

VQSR⁸ was used to filter sites. For SNPs, the GATK (version 1.3-21) UnifiedGenotyper was used to recall the sites/alleles discovered by samtools in order to generate annotations to be used for recalibration. Recalibration for the INDELS used annotations derived from the built-in samtools annotations. The GATK VariantRecalibrator was then used to model the variants, followed by GATK ApplyRecalibration, which assigns VQSLOD (variant quality score log odds ratio) values to the variants. For more detailed information on VQSR, see http://www.broadinstitute.org/gsa/wiki/index.php/Variant_quality_score_recalibration. SNPs and INDELS were modeled separately, with parameters given below:

1. Annotations

- SNPs: QD, DP, FS, MQ, HaplotypeScore, MQRankSum, ReadPosRankSum, InbreedingCoeff
- INDELS: MSD, MDV, MSQ, ICF, DP, SB, VDB

2. Training set

- SNPs: HapMap 3.3: hapmap_3.3.b37.sites.vcf, Omni 2.5M chip: 1000G_omni2.5.b37.sites.vcf
- INDELS: Mills-Devine, 1000 Genomes Phase I

3. Truth Set

- SNPs: HapMap 3.3: hapmap_3.3.b37.sites.vcf
- INDELS: Mills-Devine

4. Known Set

- SNPs: dbSNP build 132: dbsnp_132.b37.vcf
- INDELS: Mills-Devine

The truth-set sites are defined as truly showing variation from the reference. VQSLOD scores are calibrated by how many of the truth sites are retained when sites with a VQSLOD score below a given threshold are filtered out. For single-nucleotide variants sites a truth sensitivity of 99.5%, which corresponded to a minimum VQSLOD score of -0.6804 was selected, that is, for this threshold 99.5% of truth sites were retained. For INDEL sites a truth sensitivity of 97%, which corresponded to a minimum VQSLOD score of 0.5939 was chosen. Finally, we also introduced the filter $P < 10^{-6}$ to remove sites that failed the Hardy-Weinberg equilibrium.

The VQSLOD score and other annotations from GATK (BaseQRankSum, Dels, FS, HRun, HaplotypeScore, InbreedingCoeff, MQ0, MQRankSum, QD,

ReadPosRankSum, culprit) were copied back to the original samtools calls, excluding annotations which already existed in or did not apply to the samtools VCFs (DP and MQ, AC, AN). Each VCF further contained the filters LowQual (a low-quality variant according to GATK) and MinVQSLOD (Variant's VQSLOD score is less than the cutoff). All sites that did not fail these filters were marked as PASS and brought forward to the genotype refinement stage.

Of the 4,030 samples (1,990 TwinsUK and 2,040 ALSPAC) that were submitted for sequencing, 3,910 samples (1,934 TwinsUK and 1,976 ALSPAC) were sequenced and went through the variant calling procedure. Low-quality samples were identified before the genotype refinement by comparing the samples to their GWAS genotypes using about 20,000 sites on chromosome 20. Comparing the raw genotype calls to existing GWAS data, we removed a total of 112 samples (64 TwinsUK and 48 ALSPAC) because of one or more of the following causes: (i) high overall discordance to SNP array data ($> 3\%$; 55 TwinsUK and 36 ALSPAC), (ii) heterozygosity rate $> 3SD$ from population mean (1 TwinsUK and 1 ALSPAC), suggesting contamination (iii) no SNP array data available for that sample (7 TwinsUK and 0 ALSPAC) and (iv) sample below 4x mean coverage (1 TwinsUK and 11 ALSPAC). Overall, 3,798 samples (1,870 TwinsUK and 1,928 ALSPAC) were brought forward to the genotype refinement step.

The missing- and low-confidence genotypes in the filtered VCFs were filled out through an imputation procedure with BEAGLE 4 (rev909) (ref. 9).

Additional sample-level QC steps were carried out on refined genotypes, leading to the exclusion of additional 17 samples (16 TwinsUK and 1 ALSPAC) because of one or more of the following causes: (i) non-reference discordance (NRD) with GWAS SNP data $> 5\%$ (12 TwinsUK and 1 ALSPAC), (ii) contamination identified by multiple relations to other samples (13 TwinsUK and 1 ALSPAC), (iii) failed sex check (3 TwinsUK and 0 ALSPAC). To identify contamination we pruned the WGS data to a set of independent SNPs and calculated genome-wide average identity by state between each pair of samples across the two cohorts. Samples were removed if they had > 25 relations with $IBS > 0.125$ (a high number of relationships may indicate contamination). The resulting set of contaminated samples corresponded almost completely to the set of samples with $NRD > 5\%$. This left a final set of 3,781 samples (1,854 TwinsUK and 1,927 ALSPAC). These VCF files were submitted to the EGA.

Evaluation of imputation accuracy in the UK10K project. The UK10K final release WGS data of 3,781 samples and 45,492,035 sites was used for creation of haplotype reference WGS data sets. For each chromosome, a summary file was first generated and merged with that of the 1000GP WGS data to identify multi-allelic sites, sites with inconsistent alleles with that of the 1000GP data, and singletons not existing in 1000GP. These sites were excluded to create a new set of VCF files, leaving 26,032,603 sites. The VCF-QUERY tool was used to convert the new VCF files into phased haplotypes and legend files for IMPUTE2. VCF files were converted to binary ped (bed) format and multi-allelic sites excluded, and files were then split into 3MB chunks with ± 250 kb flanking regions. SHAPEIT v2 was used to re-phase the haplotypes. Phasing information from the SHAPEIT output was copied back to the original VCF files, with the phase removed for sites missing due to the MAF cutoff. The phased chunks were then recombined with vcf-phased-join from the vcftools package¹⁵.

The 1000GP Phase I integrated variant set release (v3) for low-coverage whole-genomes in NCBI build 37 (hg19) coordinates was downloaded from 1000GP FTP site (<ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20110521/>, 23 November 2010 data freezes). This callset includes phased haplotypes for 1,092 individuals and 39,527,072 variants (22 autosome and chromosome X). The haplotypes were inferred from a combination of low-coverage genome sequence data, and they contain SNPs, short INDELS, and large deletions. For each chromosome, a summary file was first generated and merged with that of the UK10K WGS data to identify multi-allelic sites and singletons not polymorphic in UK10K. These sites were excluded to create a new set of VCF files. The final reference panel included all 1,092 samples and 32,449,428 sites. The VCF-QUERY tool was used to convert the new VCF files into phased haplotypes and legend files for IMPUTE2.

A random set of 500 samples passing QC filters was chosen from the TwinsUK ($N = 1,854$) and ALSPAC ($N = 1,927$) WGS data sets. Genotypes for a total of 13,413 sites (corresponding to the content of the Illumina HumanHap610 SNP-array) on chromosome 20 were extracted from the UK10K WGS data in these 1,000 samples.

For the INCIPE study, 6,200 Caucasian participants were randomly chosen from the lists of registered patients of 62 randomly selected general practitioners based in four geographical areas in the Veneto region, North-eastern Italy¹⁶. A total of 2,258 samples were genotyped with the HumanCoreExome-12v1-1 platform. A total of 542,585 variants were called using Illumina GENCALL algorithm, 244,594 of which are exonic variants. We conducted further QC evaluation as follows to determine sample and SNP quality. At sample level, we applied the following criteria (i) sample identity was validated through genotyping with an independent typing platform (Sequenom). No samples failed this step. (ii) Twelve pairs of duplicate samples, defined as pairs of individuals with $\geq 98\%$ concordance genome-wide, were identified. The sample with the lowest call rate of the pair was excluded. (iii) Supplied gender was compared with the genotype-inferred gender (heterozygosity on sample chrX, or is the proportion of chrX SNPs called AB). A Gaussian mixture model was used to find adaptive thresholds Mmax and Fmin

(respectively, the maximum male and minimum female heterozygosity on chrX). Overall, 55 samples had chrX heterozygosities that were between M_{max} and F_{min} , and were excluded from analysis. (iv) Call rate: 90 samples with call rates below 95% were excluded from analysis. (v) 88 samples with autosomal heterozygosity (that is, the proportion of all SNPs with an heterozygous call) score ≥ 3 standard deviations away from the mean were excluded. (vi) Finally, five samples were recommended for exclusion where the normalised magnitude of intensity signal in both channels falls below 0.9. Overall, of the total of 2,258 samples genotyped, 2,145 passed QC filters while 113 samples failed QC filters as indicated above, with some samples failing multiple QC filters. At SNP level, we excluded variants with missingness rate $\geq 3\%$ or Hardy-Weinberg disequilibrium $P < 1 \times 10^{-5}$. We also checked all alleles to confirm that they are on the positive strand of the human genome by comparing alleles against the 1000G and UK10K data. At the end, there were a total of 346,941 polymorphic variants on autosomes, and 8,822 of those on chromosome 20 were retained for analysis.

Pseudo-GWAS panel: for our imputation evaluation, we used 6,300 SNPs on chromosome 20 to mimic a SNP chip in a pseudo-GWAS data set. Before imputation, the two pseudo-GWAS data sets were pre-phased using SHAPEIT v2 (ref. 11) to increase phasing accuracy. The UK10K panel was phased jointly with the entire WGS data set. The INCIPE pseudo-GWAS of 2,145 participants was pre-phased separately.

SHAPEIT v2 was also used for re-phasing the reference haplotypes provided 1000GP and UK10K projects. Per the recommendation of the software, the mean size of the windows in which conditioning haplotypes are defined is set to 0.5MB, instead of 2MB used for pre-phasing GWAS. Owing to the significantly higher number of variants in the WGS data, the re-phasing was conducted by 3MB chunk with 250 kb buffering regions, rather than by whole chromosomes as for the pseudo-GWAS. Imputation was carried out on the same chunks with the same flanking regions.

The following three steps were used to merge two WGS reference panels using IMPUTE2 (version 2.3 and later):

1. Impute the variants that are specific to panel 1 (1000GP) into panel 2 (UK10K).
2. Impute the variants that are specific to panel 2 (UK10K) into panel 1 (1000GP).
3. Treat the imputed haplotypes in both panels (with the union of variants from both) as known (that is, take the best-guess haplotypes) and impute the GWAS cohort in the usual way.

The commands for combining haplotypes with the 1000GP are given in Supplementary Note 3.

Imputation of genotypes from the three phased reference panels (UK10K, 1000GP and UK10K + 1000GP) into the two test panels was carried out on chromosome 20 split in 3MB chunks with 250 kb buffer regions. Imputation was performed using standard parameters with IMPUTE2, for example:

```
./impute2 \
-m genetic_map_chr20_combined_b37.txt \
-h chr20.uk10k.hap.gz \
-l chr20.uk10k.legend.gz \
-known_haps_g chr20.incipe2gwas.known_haps.gz \
-k_hap 10000 \
-int 3e6 6e6 \
-Ne 20000 \
-buffer 250 \
-use_prephased_g \
-o_gz \
-o chr20.01.incipe2gwas.uk10kRef.impute2
```

In Fig. 1a,d, the accuracy of imputed variants was calculated as the Pearson correlation coefficient (r^2) between imputed genotype dosages in (0–2) and masked sequence genotypes in (0,1,2). The results were stratified into non-overlapping MAF bins for plotting. In Fig. 1b,c, the numbers of variants in different imputation accuracy bins were estimated via the expected r^2 ('info') metric produced by IMPUTE2 (ref. 13). As discussed in the main text, this metric is biased upward relative to the true r^2 , so the numbers of high-confidence variants in these figures should be interpreted as upper bounds.

References

1. Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet.* **5**, e1000529 (2009).
2. Frazer, K. A. *et al.* A second generation human haplotype map of over 3.1 million SNPs. *Nature* **449**, 851–861 (2007).
3. Abecasis, G. R. *et al.* An integrated map of genetic variation from 1,092 human genomes. *Nature* **491**, 56–65 (2012).
4. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G. R. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. *Nat. Genet.* **44**, 955–959 (2012).
5. Howie, B., Marchini, J. & Stephens, M. Genotype imputation with thousands of genomes. *G3 (Bethesda)* **1**, 457–470 (2011).
6. The UK10K Consortium. The UK10K project identifies rare variants in health and disease. *Nature*. doi:10.1038/nature14962 (2015).
7. Moayyeri, A., Hammond, C. J., Valdes, A. M. & Spector, T. D. Cohort profile: twinsUK and healthy ageing twin study. *Int. J. Epidemiol.* **42**, 76–85 (2013).
8. Golding, J., Pembrey, M. & Jones, R. ALSPAC—the avon longitudinal study of parents and children. I. Study methodology. *Paediatr. Perinat. Epidemiol.* **15**, 74–87 (2001).
9. Li, H. *et al.* The sequence alignment/map format and SAMtools. *Bioinformatics* **25**, 2078–2079 (2009).
10. Browning, B. L. & Browning, S. R. A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. *Am. J. Hum. Genet.* **84**, 210–223 (2009).
11. Delaneau, O., Zagury, J. F. & Marchini, J. Improved whole-chromosome phasing for disease and population genetic studies. *Nat. Methods* **10**, 5–6 (2013).
12. Jewett, E. M., Zawistowski, M., Rosenberg, N. A. & Zollner, S. A coalescent model for genotype imputation. *Genetics* **191**, 1239–1255 (2012).
13. Marchini, J. & Howie, B. Genotype imputation for genome-wide association studies. *Nat. Rev. Genet.* **11**, 499–511 (2010).
14. Moayyeri, A., Hammond, C. J., Hart, D. J. & Spector, T. D. The UK adult twin registry (TwinsUK Resource). *Twin Res. Hum. Genet.* **16**, 144–149 (2013).
15. Danecek, P. *et al.* The variant call format and VCFtools. *Bioinformatics* **27**, 2156–2158 (2011).
16. Gambaro, G. *et al.* Prevalence of CKD in northeastern Italy: results of the INCIPE study and comparison with NHANES. *Clin. J. Am. Soc. Nephrol.* **5**, 1946–1953 (2010).

Acknowledgements

This study makes use of data generated by the UK10K Consortium. The Wellcome Trust provided funding for UK10K (award WT091310). N.S. is supported by the Wellcome Trust (Grant Codes WT098051 and WT091310), the European Commission (EUPF7 EPIGENESYS Grant Code 257082 and BLUEPRINT Grant Code HEALTH-F5-2011-282510) and the NIHR. J.B.R. is funded by the CIHR, CQDM, FRSQ and the Jewish General Hospital. H.-F.Z. is supported by Canadian Institutes of Health Research. J.M. acknowledges support from the ERC (Grant no. 617306). NJT works in a unit supported by the UK Medical Research Council (MRC) (MC_UU_12013/3). For ALSPAC, we are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. For further details concerning the generation of UK10K sequence data, please see extended methods in reference 6. Key contributing studies from the University College London-London School of Hygiene and Tropical Medicine-Edinburgh-Bristol (UCLB) Consortium appear in the lipids meta-analysis group, but we also acknowledge the support and contribution of the resource more generally. A full description of the collection and its component studies can be found here: DOI: 10.1371/journal.pone.0071345.

Author contributions

N.S. and J.M. designed the study. N.S., N.J.T., J.M., J.H. and B.H. wrote the manuscript. B.H. and J.M. developed the software. J.H. and B.H. performed the analyses. Y.M., K.W., J.L.M., P.D., H.-F.Z., S.M., J.B.R., R.D. N.J.T., E.T., G.M. and G.G. contributed materials. All authors reviewed and approved the manuscript.

Additional information

Accession Codes: UK10K reference haplotypes are available from the European Genome-phenome archive under the accession codes EGAS00001000713 (EGA study) and EGAD00001000776 (EGA dataset) under managed access conditions (http://www.uk10k.org/data_access).

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

How to cite this article: Huang, J. *et al.* Improved imputation of low frequency and rare variants using the UK10K haplotype reference panel. *Nat. Commun.* **6**:8111 doi: 10.1038/ncomms9111 (2015).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

UK10K Consortium

Saeed Al Turki^{1,13}, Antoinette Amuzu¹⁴, Carl A. Anderson¹, Richard Anney¹⁵, Dinu Antony¹⁶,
María Soler Artigas¹⁷, Muhammad Ayub¹⁸, Senduran Bala¹, Jeffrey C. Barrett¹, Inês Barroso^{1,19}, Phil Beales¹⁶,
Marianne Benn^{20,21}, Jamie Bentham²², Shoumo Bhattacharya²², Ewan Birney²³, Douglas Blackwood²⁴,
Martin Bobrow²⁵, Elena Bochukova¹⁹, Patrick F. Bolton^{26,27,28}, Rebecca Bounds¹⁹, Chris Boustred²⁹,
Gerome Breen^{27,28}, Mattia Calissano³⁰, Keren Carss¹, Juan Pablo Casas^{14,31}, John C. Chambers³²,
Ruth Charlton³³, Krishna Chatterjee¹⁹, Lu Chen^{1,12}, Antonio Ciampi³⁴, Sebahattin Cirak^{30,35}, Peter Clapham¹,
Gail Clement⁹, Guy Coates¹, Massimiliano Cocca^{36,37}, David A. Collier^{28,38}, Catherine Cosgrove²², Tony Cox¹,
Nick Craddock³⁹, Lucy Crooks^{1,40}, Sarah Curran^{26,41,42}, David Curtis⁴³, Allan Daly¹, Ian N.M. Day⁴⁴,
Aaron Day-Williams^{1,45}, George Dedoussis⁴⁶, Thomas Down^{1,47}, Yuanping Du⁴⁸, Cornelia M. van Duijn⁴⁹,
Ian Dunham²³, Sarah Edkins¹, Rosemary Ekong⁵⁰, Peter Ellis¹, David M. Evans^{3,51}, I. Sadaf Farooqi¹⁹, David R.
Fitzpatrick⁵², Paul Flicek^{1,23}, James Floyd^{1,53}, A. Reghan Foley³⁰, Christopher S. Franklin¹, Marta Futema⁵⁴, Louise
Gallagher¹⁵, Paolo Gasparini^{36,37,55}, Tom R. Gaunt³, Matthias Geihs¹, Daniel Geschwind⁵⁶, Celia
Greenwood^{5,7,34,57}, Heather Griffin⁵⁸, Detelina Grozeva²⁵, Xiaosen Guo^{48,59}, Xueqin Guo⁴⁸, Hugh Gurling⁶⁰,
Deborah Hart⁹, Audrey E. Hendricks^{1,61}, Peter Holmans³⁹, Liren Huang⁴⁸, Tim Hubbard^{1,47},
Steve E. Humphries⁵⁴, Matthew E. Hurles¹, Pirro Hysi⁹, Valentina Iotchkova^{1,23}, Aaron Isaacs⁴⁹,
David K. Jackson¹, Yalda Jamshidi⁶², Jon Johnson⁶³, Chris Joyce¹, Konrad J. Karczewski^{64,65}, Jane Kaye⁵⁸,
Thomas Keane¹, John P. Kemp^{3,51}, Karen Kennedy^{1,66}, Alastair Kent⁶⁷, Julia Keogh¹⁹, Farrah Khawaja⁶⁸,
Marcus E. Kleber⁶⁹, Margriet van Kogelenberg¹, Anja Kolb-Kokocinski¹, Jaspal S. Kooner⁷⁰, Genevieve Lachance⁹,
Claudia Langenberg⁷¹, Cordelia Langford¹, Daniel Lawson⁷², Irene Lee⁷³, Elisabeth M. van Leeuwen⁴⁹,
Monkol Lek⁶⁴, Rui Li^{5,6,7}, Yingrui Li⁴⁸, Jieqin Liang⁴⁸, Hong Lin⁴⁸, Ryan Liu⁷⁴, Jouko Lönnqvist⁷⁵,
Luis R. Lopes^{31,76}, Margarida Lopes^{1,11,77}, Jian'an Luan⁷¹, Daniel G. MacArthur^{64,65}, Massimo Mangino^{9,78},
Gaëlle Marenne¹, Winfried März^{79,80,81}, John Maslen¹, Angela Matchan¹, Iain Mathieson⁸², Peter McGuffin²⁸,
Andrew M. McIntosh²⁴, Andrew G. McKechnie^{24,83}, Andrew McQuillin⁶⁰, Sarah Metrustry⁹, Nicola Migone⁸⁴,
Hannah M. Mitchison¹⁶, Alireza Moayyeri^{9,85}, James Morris¹, Richard Morris⁸⁶, Dawn Muddyman¹,
Francesco Muntoni³⁰, Børge G. Nordestgaard^{20,21}, Kate Northstone³, Michael C. O'Donovan³⁹,
Stephen O'Rahilly¹⁹, Alexandros Onoufriadis⁴⁷, Karim Ouakacha⁸⁷, Michael J. Owen³⁹, Aarno Palotie^{1,65,88},
Kalliope Panoutsopoulou¹, Victoria Parker¹⁹, Jeremy R. Parr⁸⁹, Lavinia Paternoster³, Tiina Paunio^{75,90},
Felicity Payne¹, Stewart J. Payne⁹¹, John R.B. Perry^{9,71}, Olli Pietiläinen^{1,75,88}, Vincent Plagnol⁴³,
Rebecca C. Pollitt⁹², Sue Povey⁵⁰, Michael A. Quail¹, Lydia Quaye⁹, Lucy Raymond²⁵, Karola Rehnström¹,
Cheryl K. Ridout⁹³, Susan Ring⁹⁴, Graham R.S. Ritchie^{1,23}, Nicola Roberts²⁵, Rachel L. Robinson³³,
David B. Savage¹⁹, Peter Scambler¹⁶, Stephan Schiffels¹, Miriam Schmidts^{16,95}, Nadia Schoenmakers¹⁹,
Richard H. Scott^{16,96}, Robert A. Scott⁷¹, Robert K. Semple¹⁹, Eva Serra¹, Sally I. Sharp⁶⁰, Adam Shaw⁹⁷,
Hashem A. Shihab³, So-Youn Shin^{1,3}, David Skuse⁷³, Kerrin S. Small⁹, Carol Smees¹, George Davey Smith³,
Lorraine Southam^{1,11}, Olivera Spasic-Boskovic²⁵, Timothy D. Spector⁹, David St Clair⁹⁸, Beate St Pourcain^{3,99,100},
Jim Stalker¹, Elizabeth Stevens³⁰, Jianping Sun^{5,34}, Gabriela Surdulescu⁹, Jaana Suvisaari⁷⁵, Petros Syrris³¹,
Ioanna Tachmazidou¹, Rohan Taylor⁶⁸, Jing Tian⁴⁸, Martin D. Tobin^{17,101}, Daniela Toniolo¹⁰², Michela Traglia¹⁰²,
Anne Tybjaerg-Hansen^{21,103}, Ana M. Valdes⁹, Anthony M. Vandersteen¹⁰⁴, Anette Varbo^{20,21},
Parthiban Vijayarangakannan¹, Peter M. Visscher^{51,105}, Louise V. Wain¹⁷, James T.R. Walters³⁹,
Guangbiao Wang⁴⁸, Jun Wang^{48,59,106,107,108}, Yu Wang⁴⁸, Kirsten Ward⁹, Eleanor Wheeler¹, Peter Whincup¹⁰⁹,
Tamieka Whyte³⁰, Hywel J. Williams^{39,110}, Kathleen A. Williamson⁵², Crispian Wilson²⁵, Scott G. Wilson^{9,111,112},
Kim Wong¹, ChangJiang Xu^{5,34}, Jian Yang^{51,105}, Gianluigi Zaza¹¹³, Eleftheria Zeggini¹, Feng Zhang⁹,
Pingbo Zhang⁴⁸, Weihua Zhang³²

¹³Department of Pathology, King Abdulaziz Medical City, Riyadh, Saudi Arabia. ¹⁴London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. ¹⁵Department of Psychiatry, Trinity Centre for Health Sciences, St. James Hospital, James's Street, Dublin 8, Ireland. ¹⁶Genetics and Genomic Medicine and Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK. ¹⁷Departments of Health Sciences and Genetics, University of Leicester, Leicester LE1 7RH, UK. ¹⁸Division of Developmental Disabilities, Department of Psychiatry, Queen's University, Kingston, Canada N6C 0A7. ¹⁹University of Cambridge Metabolic Research Laboratories, and NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK. ²⁰ Department of Clinical Biochemistry and The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, 2730, Denmark. ²¹The Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark. ²²Department of Cardiovascular Medicine and Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN, UK. ²³European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, UK. ²⁴Division of Psychiatry, The University of Edinburgh, Royal Edinburgh Hospital, Edinburgh EH10 5HF, UK. ²⁵ Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge CB2 0XY, UK. ²⁶Department of Child Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, 16 De Crespigny Park, London SE5 8AF, UK. ²⁷NIHR BRC for Mental Health, Institute of Psychiatry, Psychology and Neuroscience and SLaM NHS Trust, King's College London, 16 De Crespigny Park, London SE5 8AF, UK. ²⁸MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Denmark Hill, London SE5 8AF, UK. ²⁹North East Thames Regional Genetics Service, Great Ormond Street Hospital NHS Foundation Trust, London WC1N 3JH, UK. ³⁰Dubowitz Neuromuscular Centre, UCL Institute of Child Health & Great Ormond Street Hospital, London WC1N 1EH, UK. ³¹Institute of Cardiovascular Science, University College London, Gower Street, London WC1E 6BT, UK. ³²The Department of Epidemiology and Biostatistics, Imperial College London, St. Mary's campus, Norfolk Place, Paddington, London W2 1PG, UK. ³³Leeds Genetics Laboratory, St James University Hospital, Beckett Street, Leeds, West Yorkshire, LS9 7TF, UK. ³⁴Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada H3A 1A2. ³⁵Institut für Humangenetik, Uniklinik Köln, Kerpener Str. 34, 50931 Köln, Germany. ³⁶ Institute for Maternal and Child Health-IRCCS Burlo Garofolo-Trieste, University of Trieste, 34137 Trieste, Italy. ³⁷Department of Medical, Surgical and Health Sciences, University of Trieste, 34100 Trieste, Italy. ³⁸Lilly Research Laboratories, Eli Lilly & Co. Ltd., Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK. ³⁹MRC Centre for Neuropsychiatric Genetics & Genomics, Institute of Psychological Medicine & Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK. ⁴⁰Sheffield Diagnostic Genetics Service, Sheffield Children's NHS Foundation Trust, Western Bank, Sheffield S10 2TH, UK. ⁴¹University of Sussex, Brighton BN1 9RH, UK. ⁴²Sussex Partnership NHS Foundation Trust, Swandean, Arundel Road, Worthing, West Sussex, BN13 3EP, UK. ⁴³University College London (UCL), UCL Genetics Institute, Darwin Building, Gower Street, London WC1E 6BT, UK. ⁴⁴Bristol Genetic Epidemiology Laboratories, School of Social and Community Medicine, University of Bristol, Oakfield House, Oakfield Grove, Clifton, Bristol BS8 2BN, UK. ⁴⁵Computational Biology & Genomics, Biogen Idec, 14 Cambridge Center, Cambridge, Massachusetts 02142, USA. ⁴⁶Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens 17671, Greece. ⁴⁷Department of Medical and Molecular Genetics, Division of Genetics and Molecular Medicine, King's College London School of Medicine, Guy's Hospital, London SE1 9RT, UK. ⁴⁸BGI-Shenzhen, Shenzhen 518083, China. ⁴⁹Genetic Epidemiology Unit, Department of Epidemiology, Erasmus MC, Rotterdam 3000 CA, Netherlands. ⁵⁰University College London (UCL) Department of Genetics, Evolution & Environment (GEE), Gower Street, London WC1E 6BT, UK. ⁵¹University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland 4102, Australia. ⁵²MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, at the University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK. ⁵³The Genome Centre, John Vane Science Centre, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK. ⁵⁴Cardiovascular Genetics, BHF Laboratories, Rayne Building, Institute of Cardiovascular Sciences, University College London, London WC1E 6JJ, UK. ⁵⁵Experimental Genetics Division, Sidra, P.O. Box 26999 Doha, Qatar. ⁵⁶UCLA David Geffen School of Medicine, Los Angeles, California 90095, USA. ⁵⁷Department of Oncology, McGill University, Montreal, Quebec, Canada H2W 1S6. ⁵⁸HeLEX - Centre for Health, Law and Emerging Technologies, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Oxford OX3 7LF, UK. ⁵⁹Department of Biology, University of Copenhagen, Ole Maaløes Vej 5, DK-2200 Copenhagen, Denmark. ⁶⁰University College London (UCL), Molecular Psychiatry Laboratory, Division of Psychiatry, Gower Street, London WC1E 6BT, UK. ⁶¹Department of Mathematical and Statistical Sciences, University of Colorado, Denver, Colorado 80202, USA. ⁶²Human Genetics Research Centre, St George's University of London SW17 0RE, UK. ⁶³Department of Quantitative Social Science, UCL Institute of Education, University College London, 20 Bedford Way, London WC1H 0AL. ⁶⁴Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. ⁶⁵Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA. ⁶⁶National Cancer Research Institute, Angel Building, 407 St John Street, London EC1V 4AD, UK. ⁶⁷Genetic Alliance UK, 4D Leroy House, 436 Essex Road, London N1 3QP, UK. ⁶⁸SW Thames Regional Genetics Lab, St George's University, Cranmer Terrace, London SW17 0RE, UK. ⁶⁹Vth Department of Medicine, Medical Faculty Mannheim 68167, Germany. ⁷⁰National Heart and Lung Institute, Imperial College London, London W12 0NN, UK. ⁷¹MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Box 285, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK. ⁷²Schools of Mathematics and Social and Community Medicine, University of Bristol, Oakfield House, Oakfield Grove, Clifton, Bristol BS8 2BN, UK. ⁷³Behavioural and Brain Sciences Unit, UCL Institute of Child Health, London WC1N 1EH, UK. ⁷⁴BGI-Europe, London EC2M 4YE, UK. ⁷⁵National Institute for Health and Welfare (THL), Helsinki FI-00271, Finland. ⁷⁶Cardiovascular Centre, University of Lisbon, Portugal. ⁷⁷Illumina Cambridge Ltd, Chesterford Research Park, CB10 1XL, UK. ⁷⁸National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St. Thomas' Foundation Trust, London SE1 9RT, UK. ⁷⁹Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz 8036, Austria. ⁸⁰Synlab Academy, Synlab Services GmbH, Mannheim, Germany. ⁸¹Medical Clinic V (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Diabetology), Mannheim Medical Faculty, Heidelberg University, Mannheim, 68167, Germany. ⁸²Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA. ⁸³The Patrick Wild Centre, The University of Edinburgh, Edinburgh EH10 5HF, UK. ⁸⁴Department of Medical Sciences, University of Torino, 10124, Italy. ⁸⁵Institute of Health Informatics, Farr Institute of Health Informatics Research, University College London (UCL), 222 Euston Road, London NW1 2DA, UK. ⁸⁶School of Social and Community Medicine, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK. ⁸⁷Department of Mathematics, Université de Québec À Montréal, Montréal, Québec, Canada H3C 3P8. ⁸⁸Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki FI-00014, Finland. ⁸⁹Institute of Neuroscience, Henry Wellcome Building for Neuroecology, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK. ⁹⁰University of Helsinki, Department of Psychiatry, Helsinki FI-00014, Finland. ⁹¹North West Thames Regional Genetics Service, Kennedy-Galton Centre, Northwick Park Hospital, Watford Road, Harrow HA1 3UJ, UK. ⁹²Connective Tissue Disorders Service, Sheffield Diagnostic Genetics Service, Sheffield Children's NHS Foundation Trust, Western Bank, Sheffield S10 2TH, UK. ⁹³Molecular Genetics, Viapath at Guy's Hospital, London SE1 9RT, UK. ⁹⁴ALSPAC & School of Social and Community Medicine, University of Bristol, Oakfield House, Oakfield Grove, Clifton, Bristol BS8 2BN, UK. ⁹⁵Human Genetics Department, Radboudumc and Radboud Institute for Molecular Life Sciences (RIMLS), Geert Grooteplein 25, Nijmegen, 6525 HP, The Netherlands. ⁹⁶Department of Clinical Genetics, Great Ormond Street Hospital, London, WC1N 3JH, UK. ⁹⁷Clinical Genetics, Guy's & St Thomas' NHS Foundation Trust, London SE1 9RT, UK. ⁹⁸Institute of Medical Sciences, University of Aberdeen, AB25 2ZD, UK. ⁹⁹School of Oral and Dental Sciences, University of Bristol, Lower Maudlin Street, Bristol BS1 2LY, UK. ¹⁰⁰School of Experimental Psychology, University of Bristol, 12a Priory Road, Bristol BS8 1TU, UK. ¹⁰¹National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit, Glenfield Hospital, Leicester LE3 9QP, UK. ¹⁰²Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan 20132, Italy. ¹⁰³Department of Clinical Biochemistry KB3011, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. ¹⁰⁴Maritime Medical Genetics Service, 5850/5980

University Avenue, PO Box 9700, Halifax, Nova Scotia, Canada B3K 6R8. ¹⁰⁵Queensland Brain Institute, University of Queensland, Brisbane, Queensland 4072, Australia. ¹⁰⁶Princess Al Jawhara Albrahim Center of Excellence in the Research of Hereditary Disorders, King Abdulaziz University, Jeddah, Saudi Arabia. ¹⁰⁷Macau University of Science and Technology, Avenida Wai long, Taipa, Macau 999078, China. ¹⁰⁸Department of Medicine and State Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, 21 Sassoon Road, Hong Kong. ¹⁰⁹Population Health Research Institute, St George's University of London, London SW17 0RE, UK. ¹¹⁰The Centre for Translational Omics - GOSgene, UCL Institute of Child Health, London WC1N 1EH, UK. ¹¹¹School of Medicine and Pharmacology, University of Western Australia, Perth, WA 6009, Australia. ¹¹²Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia. ¹¹³Renal Unit, Department of Medicine, University of Verona, 37126, Verona, Italy.